Tumor marker CA-125 as an evaluator and response indicator in ovarian cancer: Its quantitative correlation with tumor volume

Medical Science Monitor

Volumn 11, Issue 2, 2005, Pages

  Kumar, Pratik ^a   Rehani, Madan Mohan ^a   Kumar, Lalit ^a   Sharma, Raju ^b   Bhatla, Neerja ^b   Chaudhry, Rama ^b   Thulkar, Sanjay ^a   Sundaram, K Ramaiyer ^b   Kumar, Neeta ^b  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

CA 125; Halving time; Ovarian cancer; Quantitative correlation; Tumor marker; Tumor volume

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; TUMOR MARKER;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; ENZYME IMMUNOASSAY; EVALUATION; FEMALE; HALF LIFE TIME; HUMAN; OVARY CANCER; QUANTITATIVE ANALYSIS; RELIABILITY; TUMOR VOLUME;

CA-125 ANTIGEN; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; TIME FACTORS; TOMOGRAPHY SCANNERS, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 13844265914     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bast RC Jr, Klug TL, John E et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Eng J Med, 1983; 309: 883
2. Lavin PT, Knapp RC, Malkasian G, Whitney CW et al: CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol, 1987; 69: 223
3. Kerbs HB, Goplerud DR, Kilpatrick SJ, Myers MB et al: Role of CA 125 as tumor marker in ovarian carcinoma. Obstet Gynecol, 1986; 67: 473
4. Kumar P, Rehani MM, Kumar L et al: Potential of CT-scan based tumor volume as a response indicator in chemotherapy of advanced epithelial ovarian cancer. Med. Sci Monit, 2002; 8(10): CR667-CR674
5. Kumar P, Rehani MM, Anand V et al: Assessment of lymphnode tumor mass from CT scans: How good is diameter and visual assessment? J Med Phys, 1995; 20: 24
6. Canney PA, Moore M, Wilkinson PM, James RD: Ovarian cancer antigen CA 125: A prospective clinical assessment of its role as a tumor marker. Br J Cancer, 1984; 50: 765
7. Creiokshank DJ, Terry PB, Fullerton W: CA 125 response assessment in epithelial ovarian cancer. Int J Cancer, 1992; 51(1): 58
8. Kabawat RC, Bast Rc Jr, Welch WR et al: Immunopathic characterization of a monoclonal antibody that recognize common surface antigens of human ovarian tumors of serous, endometrial and clear cell types, Am J Clin Pathol, 1983; 79: 98
9. Atack DB, Miskar JA, Allen HH et al: CA 125 surveillance and second look laparatomy in ovarian carcinoma. Am J Obstet Gynecol, 1986; 154: 287
10. Hawkis RE, Robert K, Wiltshaw E et al: The prognostic significance of the half life of serum CA 125 inpatients responding to chemotherapy for epithelial ovarian carcinoma. Br. J Obstet, Gynecol, 1989; 96: 1395
11. Hunter VJ, Daly L, Helms M, Soper JT et al: The prognostic significance of CA 125 half life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol, 1990; 163: 1164
12. Rustin GJS, Nelstrop AE, Moclean P et al: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol, 1996; 14: 1545
13. Barber HRK: Tumor markers in ovarian cancer: In: Ovarian Carcinoma: Etiology, diagnosis and treatment. Springer-Verlag. New York, USA, 1993
14. Piver MS, Fanning J, Craig KA, Ovarian Cancer: In: Knapp RC and Berkowitz RS, Editors. Gynecologic Oncology. McGraw-Hill International Editions, Singapore, 1993